Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance, Inc (WBA) CEO Stefano Pessina on Q3 2019 Results - Earnings Call Transcript

The pharmacy giant continues to face major headwinds. But it managed to perform better than expected in Q3.

Walgreens Boots Alliance Tops Q3 Earnings Estimates, but Growth Remains Elusive

Walgreens earnings for the company's fiscal third quarter of the year have WBA stock up Thursday on an EPS and revenue beat.
The post Walgreens Earnings: WBA Stock Surges on Q3 Beat appeared first on InvestorPlace.

Walgreens Earnings: WBA Stock Surges on Q3 Beat

Walgreens Boots Alliance Inc. (NASDAQ: WBA) released its fiscal third-quarter financial results before the markets opened on Thursday.

How Walgreens Turned Itself Around in Q3

Drugstore chain Walgreens Boots Alliance Inc. (NASDAQ:WBA) reported strong third-quarter results before the opening bell on Thursday, sending shares higher in premarket trading.

Walgreens’ Shares Pop on Higher Prescription Drug Sales

Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip

Walgreens Boots Alliance (NASDAQ: WBA) reported third-quarter earnings of $1.47 per share, which beat the analyst consensus estimate of $1.43.

Walgreens Trades Higher After Q3 Earnings Beat

Walgreens (WBA) delivered earnings and revenue surprises of 3.52% and 0.16%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Q3 Earnings and Revenues Surpass Estimates

Shares of Walgreens Boots Alliance Inc. WBA, -1.08% ticked up 1% in Thursday premarket trade after the company reported third-quarter earnings and revenue that beat Wall Street expectations.

Walgreens stock up 1% after earnings beat

Walgreens Boots Alliance reported fiscal third quarter earnings that beat Wall Street's expectations Thursday before market open.

Walgreens posts quarterly earnings beat

The newest component of the Dow Jones Industrial Average is set to release its earnings report on Thursday morning.

Walgreens May Have Positive Weekly Chart on Earnings Beat

Walgreens (NYSE:WBA) is set to announce its Q3 2019 (ended May 2019) results on June 27, 2019, followed by a conference call with analysts. The market expects the company to report revenue close to $34.5 billion in Q3 2019 (ended May 2019), which would be an increase of 0.4 % y-o-y.

Walgreens To Continue Revenue Growth In Q3 2019?

Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).

Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?

FedEx

Micron Technology

NIKE

The latest earnings reporting season has largely wound down, but a few major companies have yet to share their off-season results.

Nike, Micron, Walgreens, FedEx, and More Major Earnings Coming This Week

Dow Inc

Pfizer

UnitedHealth Group

The markets have been on a wild ride in this year. The seasonal theme of “Sell in May and go away” passed and seemingly has turned into “Hold your nose and buy in June.

5 Dow Stocks Not Allowing the DJIA a Proper Rally

Continued investments in international markets and in improving the customer experience could lead to a stock price recovery for Walgreens Boots Alliance Inc.

Why Walgreens Boots Alliance Has Investment Potential

OrganiGram Holdings Inc.

Which of these healthcare stocks is the better buy right now?

Better Buy: OrganiGram Holdings vs. Walgreens Boots Alliance

The pharmacy chain has placed a big bet on empathy.

Walgreens Has an Answer for CVS's HealthHUBs

Baidu

Biogen

Bank of New York Mellon

Vodafone Group

While gurus hold positions in these companies, the share prices and returns continue to fall.

6 Guru Stocks With Negative Returns

Caterpillar

Intel

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

It’s been a wild ride in 2019. The seasonal theme of “sell in May and go away” passed and seemingly has turned into “Hold your nose and buy in June.

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

Walgreens said in a letter reviewed by CNBC it would no longer subsidize medical benefits for former employees who hadn't turned 64 by March 31.

Walgreens cuts long-time health benefit for retired employees in 'unusual' move

Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.

Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon

CVS Health

Designer Brands

Rite Aid

Simon Property Group

Ulta Beauty

Urban Outfitters

Cannabidiol sales could tally $22 billion by 2022, and these brand-name companies want their piece of the pie.

9 Major Retailers That Are Selling CBD Products

Cardinal Health

McKesson

I suggest that investors strive to build their portfolios based on prudent fundamental realities and not simply invest with the hope that your stocks will rise.

Medical Distributors: An Industry On Sale

Kraft Heinz

Marathon Petroleum

According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows.

News for Walgreens Stock (WBA)